(Q36613951)

15 August 2017

1 reference

title

Pregabalin for the treatment of generalised anxiety disorder (English)

1 reference

15 August 2017

Stuart A Montgomery

1

1 reference

PubMed ID

17020438

15 August 2017

language of work or name

English

0 references

publication date

1 October 2006

1 reference

Expert Opinion on Pharmacotherapy

15 August 2017

1 reference

15 August 2017

7

1 reference

15 August 2017

2139-2154

1 reference

15 August 2017

15

1 reference

Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication

15 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

The epidemiology of generalized anxiety disorder in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

Generalized anxiety disorder: prevalence, burden, and cost to society.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

Correlates and short-term course of self-poisoning in adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

Factors predicting the clinical course of generalised anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

Psychopharmacologic treatment of generalized anxiety disorder and the risk of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

Prevalence and impact of generalized anxiety disorder and major depression in primary care in Belgium and Luxemburg: the GADIS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

Impact of generalized social anxiety disorder in managed care

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

Neurotic disorders and the receipt of psychiatric treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

Shortfall in mental health service utilisation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

Quality of care for primary care patients with anxiety disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

Service utilisation for anxiety in an Australian community sample.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

Results of a naturalistic longitudinal study of benzodiazepine and SSRI use in the treatment of generalized anxiety disorder and social phobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

Block by gabapentin of the facilitation of glutamate release from rat trigeminal nucleus following activation of protein kinase C or adenylyl cyclase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

Pharmacokinetics of pregabalin in subjects with various degrees of renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

Activity profile of pregabalin in rodent models of epilepsy and ataxia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

Pregabalin in generalized anxiety disorder: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

Nonorganic insomnia in generalized anxiety disorder. 1. Controlled studies on sleep, awakening and daytime vigilance utilizing polysomnography and EEG mapping.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

Sleep disturbance in generalized anxiety disorder and its treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

Chronic benzodiazepine usage and withdrawal in insomnia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

A review of drug use and driving: epidemiology, impairment, risk factors and risk perceptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

Long-term Treatment of Anxiety and Risk of Withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2139

10.1517/14656566.7.15.2139

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

17020438